Amgen and TScan Therapeutics announced a collaboration Tuesday morning to pursue novel targets in Crohn’s disease. As part of the deal, Amgen will pay TScan $30 million up front, with the potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback